$1.95
41.30% today
Nasdaq, Jan 06, 10:18 pm CET
ISIN
US23255M1053
Symbol
CYCN

Cyclerion Therapeutics,Inc. Stock price

$1.95
+0.26 15.38% 1M
-1.14 36.89% 6M
+0.68 53.54% YTD
-1.19 37.90% 1Y
-10.70 84.59% 3Y
-60.25 96.87% 5Y
-248.05 99.22% 10Y
-248.05 99.22% 20Y
Nasdaq, Closing price Tue, Jan 06 2026
+0.57 41.30%
ISIN
US23255M1053
Symbol
CYCN
Industry

Key metrics

Basic
Market capitalization
$5.4m
Enterprise Value
$850.0k
Net debt
positive
Cash
$4.6m
Shares outstanding
3.7m
Valuation (TTM | estimate)
P/E
negative | -
P/S
1.9 | -
EV/Sales
0.3 | -
EV/FCF
negative
P/B
0.6
Financial Health
Equity Ratio
92.4%
Return on Equity
-34.5%
ROCE
-38.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.9m | -
EBITDA
- | -
EBIT
$-3.6m | -
Net Income
$-2.2m | -
Free Cash Flow
$-1.4m
Growth (TTM | estimate)
Revenue
1,405.3% | -
EBITDA
- | -
EBIT
15.6% | -
Net Income
41.2% | -
Free Cash Flow
77.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-127.3%
Net
-77.0% | -
Free Cash Flow
-48.2%
More
EPS
$-0.7
FCF per Share
$-0.4
Short interest
4.2%
Employees
1
Rev per Employee
$2.0m
Show more

Is Cyclerion Therapeutics,Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Cyclerion Therapeutics,Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Cyclerion Therapeutics,Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Cyclerion Therapeutics,Inc. forecast:

Buy
86%
Hold
14%

Financial data from Cyclerion Therapeutics,Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2.86 2.86
1,405% 1,405%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.99 5.99
40% 40%
209%
- Research and Development Expense 0.50 0.50
127% 127%
17%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -3.63 -3.63
16% 16%
-127%
Net Profit -2.20 -2.20
41% 41%
-77%

In millions USD.

Don't miss a Thing! We will send you all news about Cyclerion Therapeutics,Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cyclerion Therapeutics,Inc. Stock News

Neutral
Seeking Alpha
about 7 hours ago
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript
Neutral
GlobeNewsWire
one day ago
– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept (“POC”) Study in the Second Half of 2026 – – Webcast Being Held on January 6, 2026 at 8:00 a.m. ET, Featuring Key Opinion Leader, Dr. Husseini Manji – CAMBRIDGE, Mass.
Neutral
Seeking Alpha
3 months ago
Cyclerion Therapeutics, Inc. - Pre Recorded Special Call Company Participants Regina Graul - CEO, President & Director Presentation Regina Graul CEO, President & Director Good morning, everyone. Yesterday, we announced Cyclerion's transformational relaunch as a neuropsychiatric company, supported by an MIT licensing agreement that secures foundational intellectual property.
More Cyclerion Therapeutics,Inc. News

Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Head office United States
CEO Regina Graul
Employees 1
Founded 2018
Website www.cyclerion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today